This document discusses cardiovascular risk in patients with diabetes mellitus. It notes that diabetes is considered a coronary artery disease equivalent and is a major risk factor for cardiovascular events. Patients with diabetes have significantly higher risks of coronary artery disease, heart failure, stroke and other vascular complications compared to those without diabetes. The document outlines the various modifiable and non-modifiable risk factors that further increase cardiovascular risk in patients with diabetes, including dyslipidemia, hypertension, obesity, and smoking. It summarizes the results of major clinical trials investigating the effects of intensive glycemic control on microvascular and macrovascular outcomes.
Management of CAD in Diabetes the cardiovascular equivalent is challenging.The slides take you from the epidemiology,ADD,and CV benefit and how to manage CAD
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...magdy elmasry
Cardiologists and diabetes.Target organs and action mechanism of antidiabetic drugs.Cardiovascular Outcome Trials
( CVOTs ) in Diabetes.Completed and ongoing CVOTs in type 2 diabetes.Diabetes Medications
and
Cardiovascular Impact.Recommendations for management of diabetes
Cardiovascular safety of anti-diabetic drugs.
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUMPraveen Nagula
DIABETES IS ONE OF THE MOST COMMON NONCOMMUNICABLE DISEASES WORLD WIDE.
EVERY 6 SECONDS ONE PERSON IS AFFECTED BY DIABETES..
THEME FOR 2014-2016
LETS UNITE FOR DIABETES
Management of CAD in Diabetes the cardiovascular equivalent is challenging.The slides take you from the epidemiology,ADD,and CV benefit and how to manage CAD
Cardiovascular safety of anti-diabetic drugs.Cardiovascular Outcome Trials ...magdy elmasry
Cardiologists and diabetes.Target organs and action mechanism of antidiabetic drugs.Cardiovascular Outcome Trials
( CVOTs ) in Diabetes.Completed and ongoing CVOTs in type 2 diabetes.Diabetes Medications
and
Cardiovascular Impact.Recommendations for management of diabetes
Cardiovascular safety of anti-diabetic drugs.
DIABETES AND CARDIOVASCULAR DISEASE - THE CONTINUUMPraveen Nagula
DIABETES IS ONE OF THE MOST COMMON NONCOMMUNICABLE DISEASES WORLD WIDE.
EVERY 6 SECONDS ONE PERSON IS AFFECTED BY DIABETES..
THEME FOR 2014-2016
LETS UNITE FOR DIABETES
Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia.
Several distinct types of DM are caused by a complex interaction of genetics and environmental factors.
Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production.
The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.
#flozins
🫀DAPA 🆚placebo in HFpEF
Now we have a positive trial!
⬇️18% in CV☠️ death or
worsening HF among LVEF>40%
⬇️ 21%heart failure
💥Results same for LVEF> 60% 🆚LVEF<60%
Ponencia realizada por el Prof. Alberto Zambon en la segunda sesión de CardioVascular Virtual Topic 2022, titulada Residual cardiovascular risk. What is the role of icosapent ethyl?
Diabetes mellitus (DM) refers to a group of common metabolic disorders that share the phenotype of hyperglycemia.
Several distinct types of DM are caused by a complex interaction of genetics and environmental factors.
Depending on the etiology of the DM, factors contributing to hyperglycemia include reduced insulin secretion, decreased glucose utilization, and increased glucose production.
The metabolic dysregulation associated with DM causes secondary pathophysiologic changes in multiple organ systems that impose a tremendous burden on the individual with diabetes and on the health care system.
#flozins
🫀DAPA 🆚placebo in HFpEF
Now we have a positive trial!
⬇️18% in CV☠️ death or
worsening HF among LVEF>40%
⬇️ 21%heart failure
💥Results same for LVEF> 60% 🆚LVEF<60%
Ponencia realizada por el Prof. Alberto Zambon en la segunda sesión de CardioVascular Virtual Topic 2022, titulada Residual cardiovascular risk. What is the role of icosapent ethyl?
On DPP-Inhibitor ,case study on Linagliptin,Safe and affective class of drug for Management of Type II Diabetes as Monotherapy and add on therapy with OHA and Insulin,It can be added to SGLT2 Inhibitor also.
diabetes is most prevalent disease in asia, incidence of heart failure is also increasing in diabetic population, understanding the pathophysiology is very important to deal with these cases.
GLP-1 is an incretin (hormone that increases insulin secretion in response to a meal), which is a 30-amino acid peptide secreted in response to the oral ingestion of nutrients by intestinal L cells.
GLP-1 receptors (GLP-1R) are located in islet cells, central nervous system, and other organs. GLP-1 is metabolized by the enzyme dipeptidyl peptidase-4 (DPP-4).
Incretin effect is a phenomenon whereby a glucose load delivered orally produces a much greater insulin secretion than the same glucose load administered intravenously.
This presentation is an overview of the entire GLP-1 system, followed by an introduction to leveraging its therapeutic potential using GLP-1 analogues (Exenatide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide) and DPP-4 inhibitors (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Anagliptin, Teneligliptin, Alogliptin, Trelagliptin, Omarigliptin).
Shashikiran Umakanth delivered this talk at Manipal on 30th November, 2015
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
Cardiovascular risk in patients with diabetes mellitus
1. By
Dr. Hani A.AbdelWahab, M.D.
Consultant cardiologist,AFHJ
(June/ 2nd
/2016)
Cardiovascular risk inCardiovascular risk in
patients with Diabetespatients with Diabetes
MellitusMellitus
3. It is also considered as a worldwide
epidemic and one of the most common
chronic diseases in both developed and
developing nations.
CAD accounts for as many as 80% of deaths
among individuals with DM compared
with 30% in those without DM.
4.
5. The prevalence of T2DM which correlates
closely with obesity has shown a sharp rise
over recent decades. Consequently the
management of DM & other CAD risk factors is
the main focus in the primary and secondary
prevention of cardiovascular events.
6. Diabetes is a huge and growing problem, and the costs to
society are high and escalating
382 million people have
diabetes
By 2035, this number will
rise to 592 million
IDF ,Global burden of
diabetes , 2013
7.
8.
9. The pathological continuumThe pathological continuum
Normal glucose tolerance
Impaired fasting glucose
Impaired glucose tolerance
T2DMT2DM
PREDIABETES
COMPLICATIONS
10. Impact of diabetes on CVD:Impact of diabetes on CVD:
Both T1DM and T2DM confer significantly
elevated risks (2-5 folds) of:
CAD, ACS, post MI complications.
Heart failure.
Sudden cardiac death.
PAD.
Stroke
End stage renal failure.
11.
12. Diabetes as a CHD Risk Equivalent:Diabetes as a CHD Risk Equivalent:
Type 2 DM and CHDType 2 DM and CHD
7-Year Incidence of Fatal/Nonfatal MI7-Year Incidence of Fatal/Nonfatal MI
(East West Study)(East West Study)
No Diabetes Diabetes
3.5%
18.8%
20.2%
45.0%
P<0.001 P<0.001
7-yearincidencerateofMI
CHD=coronary heart disease; MI=myocardial infarction; DM=diabetes mellitus
Haffner SM et al. N Engl J Med. 1998;339:229-234.
13. In the Framingham Heart Study, the risk of
CAD is doubled in men and tripled in women
with diabetes, compared with age-matched
subjects without diabetes.
Patients with diabetes present differently from
those without diabetes and are much more
likely to experience an acute coronary
syndrome without chest pain known as “silent
ischemia.”
14. Indeed, there are multiple studies
suggesting poorer outcomes following
cardiovascular events, even with
revascularization, for individuals with
diabetes compared with those without.
Cardiogenic shock is more common and
more severe in post-MI patients with
diabetes.
15. Risk factors for CAD in patients
with DM
The risk factors that predispose individuals
with diabetes to develop cardiovascular
disease are the same as those that raise
cardiovascular risks in those without
diabetes.
However, the prevalence of known major
risk factors for CAD is generally amplified
among persons with diabetes.
18. DyslipidemiaDyslipidemia
This is one of the most profound risk factors
among individuals with diabetes.
Diabetes is associated with:
Small, dense low-density lipoprotein (LDL)
particle composition.
Increased levels of apolipoprotein B and E.
Low levels of high-density lipoprotein (HDL)
cholesterol.
High triglyceride (TG) levels.
19.
20. Lipid-lowering therapy is now a
cornerstone of T2DM management.
In the Scandinavian Simvastatin Survival
Study (4S4S), there was a 55% reduction in
cardiovascular events among subjects with
diabetes, a 25% reduction in the CARECARE trial
and 24% reduction in the LIPIDLIPID trial with
pravastatin.
21. In the Collaborative AtoRvastatin Diabetes
Study (CARDSCARDS), atorvastatin 10 mg reduced
LDL-C by 40% on average. Results at 4 years
showed a 37% relative risk reduction (p
<0.001) in the primary endpoint & 27%
relative risk reduction in the secondary
endpoints (p=0.05).
22. HypertriglyceridemiaHypertriglyceridemia
Elevated fasting TG levels are characteristic
of the lipid panel in diabetes and constitute
an independent cardiovascular risk factor.
Hypertriglyceridemia correlates with
abdominal adiposity.
Fibrates have traditionally been considered
an appropriate therapy to target
hypertriglyceridemia and have often been
added to statin therapy for this indication.
23. HypertensionHypertension
The prevalence of hypertension is increased
in individuals with diabetes compared with
those without.
In the UKPDS, lowering the blood pressure
to a mean of 144/82 mm Hg (compared with
154/87 mm Hg) significantly reduced
strokes, diabetes related deaths, and heart
failure, as well as microvascular
complications.
24. Several trials have demonstrated the renal
protective effects of angiotensin-converting
enzyme inhibitors (ACEIs) or angiotensin
receptor antagonists (ARBs) over alternate
agents, which has firmly established them as
the first-line antihypertensives in diabetes.
There is currently insufficient evidence to
recommend ACE inhibitors in normotensive
patients with diabetes without
microalbuminuria.
25. Major guidelines suggest a target blood
pressure in patients with diabetes of < 130/80
mmHg.
The ACCORD trial randomized subjects with
diabetes to a target systolic blood pressure of <
120 mmHg or < 140 mmHg. The lower target
group showed no difference in the primary
cardiovascular outcomes end point but did
have a significantly lower stroke rate; however,
this was at the expense of significantly more
adverse drug events and an increased risk of a
creatinine rise of> 1.5 mg/dL.
27. ObesityObesity
Obesity and overweight are typically
defined in terms of body mass index (BMI),
with:
Overweight being 25 to 30 kg/m2
Class I obesity 30 to 35 kg/m2
Class II obesity 35 to 40 kg/m2
Class III obesity > 40 kg/m2
.
28. Waist circumference and waist-to-hip ratio
better reflect abdominal adiposity and are
more reliable predictors of CAD outcomes
than BMI.
T2DM correlates closely with obesity,
especially central obesity.
Caloric restriction, behavior modification,
and increased physical activity form the
basis of weight management programs.
29. Drugs for weight loss:
Sibutramine
Ephedrine and ephedra alkaloids
Phentermine and diethylpropion
Orlistat (pancreatic lipase inhibitor)
Others (antidepressants such as fluoxetine,
sertraline, bupropion & anti-epileptics such as
topiramate and zonisamide; and diabetes
medications
including metformin and the glucagon like
peptide (GLP) analogs).
30. There is growing evidence regarding the
beneficial effects of significant weight loss
achieved by bariatric surgery on glucose
metabolism.
Bariatric surgery is generally restricted to
individuals with BMI >40 kg/m2
or BMI 35
to 40 kg/m2
with co-existing medical
conditions such as diabetes.
31. Bariatric surgery options include :
Malabsorptive procedures such as the
Roux-en-Y gastric bypass.
Restrictive procedures such as
laparoscopic adjustable gastric bands and
sleeve gastrectomy.
34. Role of DM in the pathology ofRole of DM in the pathology of
atherosclerosisatherosclerosis
Diabetes accelerates the atherosclerosis
process & endothelial dysfunction.
Autopsy series have revealed more diffuse
coronary involvement, greater severity of
vessel stenosis, and more severe left main
disease in persons with diabetes, compared
with those without.
35. NONO is among several key substances that
maintain healthy endothelial function,
which includes freedom from adhesion
molecule activation, leukocyte diapedesis,
platelet aggregation, and activation of
thrombosis.
36. Current research reveals the impact of
excessive oxidative stress (which can he
induced by hyperglycemia, fatty acids, or
insulin resistance) on NONO production and
also on the generation of advanced glycation
end products (AGEPsAGEPs), which are suspected
to mediate various negative cellular effects
in diabetes.
37. DMDM
Reactive oxygen substances (ROS).
Hyperglycemia : NO by:
NO synthetase.
Its degradation by formation of ROS
through protein kinase C, NADPH oxidases
and AEGs (Advanced End Glycation
Products).
40. Platelet function is also abnormal in
diabetes, with overexpression of the
glycoprotein IIb/IIIa receptor promoting
inappropriate platelet adhesion and
activation.
Vasoconstriction by:
Endothelin-1 , Angiotensin II &
prostanoids , V.C. response to
catecholamines (autonomic dusfunctionautonomic dusfunction).
43. MICROVASCULAR TRIALSMICROVASCULAR TRIALS
The role of tight control of glycemia was
firmly established in the 1990s with the
publication of two large trials demonstrating
decreases in microvascular complications
nephropathy and retinopathy with lower
glucose goals.
44. In summary,
The two large trials published in the 1990s,
DCCT and UKPDS,DCCT and UKPDS, showed significant
improvements in microvascular outcomes
with tighter glycemic control in T1DM or
T2DM.
45. MACROVASCULAR TRIALSMACROVASCULAR TRIALS
Despite the convincing evidence for a
reduction in microvascular complications,
the relationship between glycemia and
cardiovascular events remained unclear,
with neither DCCT nor UKPDS showing a
definitive advantage in terms of
cardiovascular outcomes or mortality.
46. Three further large trials added additional
information regarding the potential
relationship between glycemic control and
cardiovascular outcomes.
47. The ADVANCEADVANCE trial (Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified
Release Controlled Evaluation) randomized 11,140
patients with T2DM to standard versus
intensive glucose control.
Intensive control was achieved with the use
of gliclazide (a sulfonylurea) plus other
agents as necessary to achieve a HbAlc 6.5%
48. There was a decrease in the incidence of
microvascular events (primarily
macroalburninuria) but no significantno significant effect
of the type of glucose control on major
macrovascular events.
49. The ACCORD trialThe ACCORD trial (Action to Control
Cardiocascular Risk in Diabetes) also tested the
effects of tight glucose control, recruiting a
total of 10,251 T2DM patients who were
randomized to a target HbAlc of < 6% versus
7.0% to 7.9%
50. ACCORD was discontinued at a meanACCORD was discontinued at a mean
follow-up of 3.5 years due to an increasedfollow-up of 3.5 years due to an increased
risk of death in the intensive treatment arm.risk of death in the intensive treatment arm.
Hypoglycemia requiring medical attention
and weight gain > 10 kg were both more
common in the intensive therapy group.
51. Trials Show No Reduction in CV Events withTrials Show No Reduction in CV Events with
More Intensive Glycemic ControlMore Intensive Glycemic Control
1
ACCORD Study Group. N Engl J Med. 2008;358:2545-2559.
2
ADVANCE Collaborative Group. N Engl J Med. 2008;358:2560-2572.
Number at Risk
Intensive 5570 5369 5100 4867 4599 1883
Standard 5569 5342 5065 4808 4545 1921
25
20
15
10
5
0
0 12 24 36 48 60
Cumulativeincidence(%)
Months of follow-up
Standard therapy
Intensive therapy
ADVANCE: Primary Outcome
Number at Risk
Intensive 5128 4843 4390 2839 1337 475 448
Standard 5123 4827 4262 2702 1186 440 395
Patientswithevents(%)
0 1 2 3 4 5 6
25
20
15
10
5
0
Years
Standard therapy
Intensive therapy
ACCORD: Primary Outcome
52. In the VADTVADT (Veterans Affairs Diabetes Trial)
there was no significant difference observed
between the two groups in any component
of the primary outcome or in all-cause
mortality.
53.
54. The 2009 ACC/AHA Scientific Statement
supports a goal HbA1c of ≤ 7a goal HbA1c of ≤ 7 with
acknowledgment of the benefits of tight
control in terms of microvascular disease,
but recognizes the paucity of evidence for a
cardiovascular benefit.
55. Diabetic CardiomyopathyDiabetic Cardiomyopathy
One reason for the poor prognosis in
patients with both diabetes and ischemic
heart disease seems to be an enhanced
myocardial dysfunction leading to
accelerated heart failure.
Thus, patients with diabetes are unusually
prone to congestive heart failure.
56. Several factors probably underlie diabetic
cardiomyopathy:
Accelerated coronary atherosclerosis.
Prolonged hypertension.
Chronic hyperglycemia, microvascular
disease, endothelial dysfunction, altered
calcium handling, accumulation of AGEPs
and FFAs, glycosylation of myocardial
proteins, and autonomic neuropathy.
57. Guide toGuide to
Comprehensive RiskComprehensive Risk
Reduction forReduction for
Patients WithPatients With
Coronary and OtherCoronary and Other
Vascular DiseaseVascular Disease
Who Have DiabetesWho Have Diabetes
58. Lifestyle Modifications for primaryLifestyle Modifications for primary
and secondary prevention of CADand secondary prevention of CAD
5-Avoid tobacco
(JNC VI. Arch Intern Med. 1997)
1- Reduce weight 3-Moderate consumption
of:
• Sodium (6gm/day)
• saturated fat
• cholesterol
2-Increase
physical
activity
(30-40
min/day)
4-Maintain adequate intake of dietary:
• potassium
• calcium
• magnesium
61. Smoking CessationSmoking Cessation
Strongly encourage patient and family to
stop smoking.
Provide counseling, nicotine replacement,
and formal cessation programs as
appropriate.
62. Blood pressure controlBlood pressure control
Initiate lifestyle modification, weight
control, physical activity, alcohol and
smoking cessation, and moderate sodium
restriction in all patients with blood
pressure > 130 mm Hg systolic or 85 mm Hg
diastolic.
Goal: ≤ 130/85 mm HgGoal: ≤ 130/85 mm Hg
63. Add blood pressure medication according
to other patient requirements and
characteristics (i.e. age, race, compelling
indications) if:
BP is not < 140 mm Hg systolic or < 90 mm
Hg diastolic in 3 months or if initial BP is >
160 mm Hg systolic or > 100 mm Hg
diastolic.
Type 2 Diabetes and CHD 7-Year Incidence of Fatal/Nonfatal MI (East West Study)
Prior to completion of this study, little data existed to compare mortality rates from coronary heart disease (CHD) in patients with diabetes, but without prior myocardial infarction (MI), and patients without diabetes, but with a history of MI. To sort out the risks among the groups and determine whether patients with diabetes and no MI history should be treated as aggressively for cardiovascular (CV) risk factors as patients who have had an MI, the 7-year incidence MI in 2432 patients (1059 with diabetes, 1373 without diabetes) was quantified.
Results indicate, the 7-year incidence of MI in patients with diabetes was 45.0% for those with a previous MI, and 20.2% for patients without an MI at baseline (P&lt;0.001). Among patients without diabetes, but with a positive history for prior MI, 7-year incidence of MI was 18.8%. Kaplan-Meier estimates that the probability of death from CHD reveals similar outcomes for patients with diabetes/no history of MI and no diabetes/history of MI. The hazard ratio for death from CHD for the 2 groups was not significantly different from 1.0 (hazard ratio, 1.4; 95% confidence interval [CI]) of 0.7 to 2.6). This hazard ratio remained close to 1.0 even after adjustment for total cholesterol, hypertension, and smoking.
These data support that treatment of CV risk factors in patients with diabetes and no history of MI should be as aggressively treated as with patients without diabetes, but with a history of previous MI.
Reference
Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
A key concept of cardiometabolic risk is that the risk factors tend to cluster, as illustrated in this diagram. The cardiovascular and metabolic variables are often associated with each other and therefore can occur simultaneously. In recent years, the clustering of cardiometabolic risk factors has received increasing attention, leading groups such as the World Health Organization, International Diabetes Federation, and the Adult Treatment Panel III (ATP III) (National Cholesterol Education Program) to issue clinical guidelines for identifying this particular group of risk factors as the metabolic syndrome.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.